Catalent Inc (CTLT.N)
22 Jun 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|53||2016||Chairman of the Board, President, Chief Executive Officer|
|45||2018||Chief Financial Officer, Senior Vice President|
|52||2013||President - Softgel Technologies|
|51||2013||President - Drug Delivery Solutions|
|55||2014||Senior Vice President, General Counsel and Corporate Secretary|
- BRIEF-Catalent Reports Q3 Earnings Per Share Of $0.14
- BRIEF-Biohaven Says Expects Topline Results From Phase 3 Trial With Rimegepant Zydis ODT In Q4
- BRIEF-Biohaven Announces Positive Results With Sublingual Rimegepant Zydis Orally Dissolving Tablet
- BRIEF-Biohaven Announces License Agreement With Catalent For Zydis ODT With Small Molecule Cgrp Receptor Antagonists
- BRIEF-Catalent Announces Changes To Its Board Of Directors